Interview with Dr. John R. Thornback, Chief Executive Officer, Dx assays
Nine months ago you were appointed CEO of the company. What brought you to Dx assays? I think Dx Assays is a very interesting opportunity, which is why I came…
Address: Unit #02-01/02/03, Blk 35 Marsiling Ind Estate Road 3, Woodlands Central Industrial Estate, Singapore 739257,Singapore
Tel: +65 6499 0720
Dx assays mission is to provide high-quality molecular assay development and assay validation to their customers with speed and efficiency, coupled with their fee-for-service and co-development business model, Dx assays focus on ‘delivering your success’.
Their laboratories are equipped with the state-of-the-art technologies and are operated by highly qualified personnel according to CE and FDA requirements. They provide fully ISO 9001 and ISO 13485 accredited processes and procedures which gives its clients a guarantee of high quality product development and documentation that meets regulatory requirements
Dx assays provide advanced molecular diagnostic assay development, verification, validation, and high quality product enhancement services. They have a proven track record and have delivered successful projects to a wide variety of pharmaceutical, clinical and diagnostic customers all around the world.
Nine months ago you were appointed CEO of the company. What brought you to Dx assays? I think Dx Assays is a very interesting opportunity, which is why I came…
To cater to Japan and Asia Pacific (JAPAC)’s booming biotech industry, in May 2021 IQVIA expanded its ‘IQVIA Biotech’ brand into the region. Looking ahead to 2022, IQVIA Biotech JAPAC…
Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for…
Asia has experienced a biotech boom in the past five years. In 2020, almost 50 percent of the region’s clinical trials were led by biotechs and by 2025, biotech-led clinical…
Angeline Ho gives an overview of the patient advocacy landscape in Asia-Pacific, why an Asian model of patient engagement – distinct from those in Europe and the US – needs…
The Asia-Pacific (APAC) region is home to around 1.44 billion people, over 60 percent of the world’s population, and a vast diversity of cultures, infrastructures, and economic development. Managing a…
Ashish Mahajan, Partner in Deloitte’s Life Sciences and Healthcare Consulting Practice in Southeast Asia, outlines some of the key trends playing out in the region, the extent to which the…
Professor Subra Suresh, president of Nanyang Technological University (NTU) and former director of the US National Science Foundation, explains how the university has managed to consistently be among the top…
Marco Lee, APAC head for medical device firm Avanos explains how the company’s products are catered to patient needs in the region and talks through key growth drivers, the impact…
AstraZeneca (AZ)’s country president for Singapore, Vinod Narayanan, outlines the challenges of taking the reins at an affiliate against the backdrop of a pandemic and how the Anglo-Swedish company’s quest…
One of the main supporting pillars of Singapore’s pharmaceutical industry is its magnificent manufacturing base. Not only does the city-state rank as one of the few countries on the planet…
Cindy Engelbart, director of mid-sized logistics player Agility’s life science operations in APAC, highlights some of the key trends in global logistics that have emerged from the COVID-19 pandemic, how…
In 2020, the FDA granted its first approval to a comprehensive liquid biopsy, potentially representing a paradigm shift towards using liquid biopsies upfront as an easier, safer, faster, and more…
See our Cookie Privacy Policy Here